Clinical TrialMay 4, 2026, 08:31 AM
FibroBiologics Releases CYWC628 Drug Product for DFU Trial
AI Summary
FibroBiologics, Inc. announced the release of the first batch of its CYWC628 drug product, which will support its Phase 1/2 clinical trial for patients with diabetic foot ulcers (DFUs). The product was manufactured under cGMP and successfully passed all required safety and quality testing, enabling patient enrollment. This marks a significant step in evaluating the safety, tolerability, and preliminary efficacy of CYWC628, an investigational fibroblast-based therapy.
Key Highlights
- FibroBiologics released the first batch of its CYWC628 drug product.
- The drug product will support its Phase 1/2 clinical trial for diabetic foot ulcers (DFUs).
- CYWC628 was manufactured under cGMP and passed all safety and quality testing.
- This milestone enables the company to begin enrolling patients in the DFU trial.
- CYWC628 is an investigational fibroblast-based therapy for chronic DFUs.
- FibroBiologics holds over 270 issued and pending patents.
Price Impact
More from FBLG